Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) that has activating genetic changes of the MET gene (mutation or amplification \[increase number of gene copies\]). Testing for tumor gene changes can be performed in tumor tissue or blood samples. Patients must have previously received treatment with chemotherapy. The number of patients to be enrolled will depend on how many enrolled patients experience tumor size reduction. MGCD265 will be administered orally, twice daily. The study is designed to evaluate whether the number of patients experiencing tumor size reduction is substantially higher than would be expected with other available treatments.
Checked against the public recordLast updated Mar 4, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Mirati Therapeutics Inc.
- Interventions being studied
- Drug: MGCD265
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Diagnosis of non-small cell lung cancer * Metastatic or locally advanced disease * Prior platinum chemotherapy or immunotherapy * Test result showing genetic change in MET tumor gene * At least one tumor that can be measured on a radiographic scan Exclusion Criteria: * Prior treatment with inhibitor of MET or HGF * Prior positive test for EGFR mutation or ALK gene rearrangement * Uncontrolled tumor in the brain
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Alabama at BirminghamBirmingham, Alabama
- Clearview Cancer InstituteHuntsville, Alabama
- Fowler Family Center for Cancer CareJonesboro, Arkansas
- Providence Saint Joseph Medical CenterBurbank, California
- Saint Joseph Heritage HealthcareFullerton, California
- University of California San DiegoLa Jolla, California
- Loma Linda University Medical CenterLoma Linda, California
- University of California, San FranciscoSan Francisco, California
- Innovative Clinical Reseach InstituteWhittier, California
- St. Mary's Regional Cancer CenterGrand Junction, Colorado
- Eastern Connecticut Hematology and Oncology AssociatesNorwich, Connecticut
- Georgetown University Medical CenterWashington D.C., District of Columbia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 4, 2020. Always confirm current availability with the study team.